{
    "clinical_study": {
        "@rank": "131003", 
        "arm_group": [
            {
                "arm_group_label": "Group Tdap", 
                "arm_group_type": "Experimental", 
                "description": "Subjects who had received Boostrix\u2122 vaccine in study NCT00109330 and will receive a second dose of Boostrix\u2122 vaccine."
            }, 
            {
                "arm_group_label": "Group Td", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects who had received control Td vaccine in study NCT00109330 and will receive the first dose of Boostrix\u2122 vaccine."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this follow-up study is to evaluate the persistence of antibodies against all\n      the vaccine antigens 10 years after booster vaccination with either Tdap or Td, and also to\n      assess immunogenicity and safety of another dose of Boostrix, administered in this study.\n      This protocol posting deals with objectives and outcome measures of the extension phase. The\n      objectives and outcome measures of the primary phase are presented in a separate protocol\n      posting (NCT number = NCT00109330)."
        }, 
        "brief_title": "Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix\u2122 Vaccine in Previously Boosted Young Adults", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Tetanus", 
            "Acellular Pertussis", 
            "Diphtheria"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diphtheria", 
                "Whooping Cough", 
                "Tetanus"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subjects were previously vaccinated with either Boostrix or a control Td vaccine in study\n      NCT00109330. Only subjects who were part of the primary study will be invited to participate\n      in this study. All subjects will receive a single dose of Boostrix at Visit 1 (Day 0) and\n      subjects will be observed till Visit 2 (Day 30) for safety in terms of solicited adverse\n      events (during 4 days post vaccination), unsolicited adverse events (during 31 days post\n      vaccination) and serious adverse event (during the trial period). A blood sample will be\n      collected from all subjects before vaccination (Visit 1) and one month after vaccination\n      (Visit 2) for antibodies estimation.\n\n      This summary has been updated following Protocol amendment 2 dated 03 October 2013. The\n      protocol is being amended to facilitate enrolment by:\n\n        -  -  Extending the window period for re-vaccination from \u00b1 6 months to \u00b1 300 days from\n           the Year 10 time point.\n\n        -  -  Extending the recruitment period from 6 months to 14 months. The format of\n           non-inferiority criterion of the first co-primary objective has been updated to keep it\n           aligned with the format of non-inferiority criterion of the second co-primary\n           objective."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who, in the opinion of the investigator, can and will comply with the\n             requirements of the protocol (e.g. completion of the diary cards, return for\n             follow-up visit).\n\n          -  Subjects who have received a dose of Tdap or Td vaccines 10 years (+/-300 days) back,\n             in study NCT00109330.\n\n          -  Written informed consent obtained from the subject.\n\n          -  Healthy subjects as established by medical history and clinical examination before\n             entering into the study.\n\n          -  Female subjects of non-childbearing potential may be enrolled in the study.\n\n               -  Non-childbearing potential is defined as pre-menarche, current tubal ligation,\n                  hysterectomy, ovariectomy or post-menopause.\n\n          -  Female subjects of childbearing potential may be enrolled in the study, if the\n             subject\n\n               -  has practiced adequate contraception for 30 days prior to vaccination, and\n\n               -  has a negative pregnancy test on the day of vaccination, and\n\n               -  has agreed to continue adequate contraception during the entire treatment period\n                  and for 1 month after completion of the vaccine dose.\n\n        Exclusion Criteria:\n\n          -  Use of any investigational or non-registered product (drug or vaccine) other than the\n             study vaccine within 30 days preceding the dose of study vaccine, or planned use\n             during the study period.\n\n          -  Chronic administration (defined as more than 14 days in total) of immunosuppressants\n             or other immune-modifying drugs within six months prior to the booster vaccine dose .\n             For corticosteroids, this will mean prednisone (\u2265 20 mg/day (for adult subjects), or\n             equivalent. Inhaled and topical steroids are allowed.\n\n          -  Planned administration/administration of a vaccine not foreseen by the study protocol\n             in the period starting 30 days before and ending 31 days after the dose of vaccine,\n             with the exception of Influenza vaccine which is allowed throughout the study period.\n\n          -  Concurrently participating in another clinical study, at any time during the study\n             period, in which the subject has been or will be exposed to an investigational or a\n             non-investigational vaccine/product (pharmaceutical product or device).\n\n          -  Previous vaccination against diphtheria, tetanus or pertussis since the last dose\n             received in the Study NCT00109330.\n\n          -  History of diphtheria, tetanus or pertussis diseases following the receipt of booster\n             dose in the Study NCT00109330.\n\n          -  Severe allergic reaction (e.g. anaphylaxis) after previous administration of any\n             tetanus toxoid, diphtheria toxoid, or pertussis-antigen containing vaccines, or any\n             component of Boostrix.\n\n          -  Hypersensitivity to latex.\n\n          -  Encephalopathy (e.g. coma, decreased level of consciousness, prolonged seizures) of\n             unknown etiology occurring within 7 days following previous vaccination with\n             pertussis-containing vaccine.\n\n          -  History of any neurological disorders or seizures.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on\n             medical history and physical examination (no laboratory testing required).\n\n          -  Acute disease and/or fever at the time of enrolment.\n\n               -  Fever is defined as temperature \u2265 99.5\u00b0F for oral, axillary or tympanic route,\n                  or  \u2265 100.4\u00b0F for rectal route. The preferred route for recording temperature in\n                  this study will be oral.\n\n               -  Subjects with a minor illness (such as mild diarrhea, mild upper respiratory\n                  infection) without fever may, be enrolled at the discretion of the investigator.\n\n          -  Administration of immunoglobulins and/or any blood products within the 3 months\n             preceding the booster dose of study vaccine or planned administration during the\n             study period.\n\n          -  Pregnant or lactating female.\n\n          -  Female planning to become pregnant or planning to discontinue contraceptive\n             precautions up to 1 month post-vaccination."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "30 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "165", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01738477", 
            "org_study_id": "116570"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group Tdap", 
                "Group Td"
            ], 
            "description": "Single dose intramuscular administration.", 
            "intervention_name": "Boostrix", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Booster", 
            "Tdap", 
            "Immunogenicity", 
            "Repeat dose", 
            "Safety", 
            "BoostrixTM", 
            "Persistence"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Mesa", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85282"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tempe", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85283"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jonesboro", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72401"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fullerton", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92835"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rolling Hills Estates", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90274"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Golden", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80401"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norwich", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06360"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32209"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60614"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bardstown", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40004"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Woburn", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01801"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68131"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stony Brook", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11794-8111"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44109"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44121"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Erie", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16505"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Upper St. Clair", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15241"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84109"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "South Jordan", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84095"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluation of Immunogenicity and Safety of GSK Biologicals' Tdap Booster Vaccine (Boostrix\u2122) in Young Adults, Administered 10 Years After Previous Tdap Boosting", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Immunogenicity with respect to components of the study vaccine in terms of seroprotection/geometric mean antibody concentrations (GMCs).", 
            "safety_issue": "No", 
            "time_frame": "One month after vaccination with BoostrixTM (Month 1)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01738477"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Immunogenicity with respect to components of the study vaccine in terms of antibody concentrations, seropositivity and vaccine response.", 
                "safety_issue": "No", 
                "time_frame": "Before (Day 0) and one month after vaccination with BoostrixTM (Month 1)."
            }, 
            {
                "measure": "Occurrence of solicited local and general symptoms.", 
                "safety_issue": "No", 
                "time_frame": "During the 4 days (Day 0 - 3) follow-up period after vaccination with BoostrixTM."
            }, 
            {
                "measure": "Occurrence of unsolicited adverse events.", 
                "safety_issue": "No", 
                "time_frame": "During the 31 days (Day 0 - 30) after vaccination with BoostrixTM."
            }, 
            {
                "measure": "Occurrence of serious adverse events.", 
                "safety_issue": "No", 
                "time_frame": "From Day 0 to 31 days post-vaccination."
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}